Wayne A.I. Frederick Sells 1,825 Shares of Insulet Co. (NASDAQ:PODD) Stock

Insulet Co. (NASDAQ:PODD) Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Insulet Trading Down 1.7 %

Insulet stock opened at $260.27 on Friday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The stock has a market capitalization of $18.28 billion, a PE ratio of 44.95, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The firm has a 50 day simple moving average of $272.03 and a 200-day simple moving average of $258.25. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, equities research analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Insulet

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SBI Securities Co. Ltd. acquired a new stake in Insulet during the fourth quarter valued at approximately $36,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Insulet during the 4th quarter valued at $42,000. SRS Capital Advisors Inc. boosted its stake in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares in the last quarter. TD Private Client Wealth LLC grew its holdings in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the last quarter. Finally, Friedenthal Financial acquired a new stake in shares of Insulet during the fourth quarter worth $57,000.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on PODD shares. Stifel Nicolaus lifted their price target on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a report on Friday, February 21st. Canaccord Genuity Group lifted their target price on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Royal Bank of Canada began coverage on Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Finally, TD Cowen upped their price objective on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average price target of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.